Uncategorized

Immunovant’s FcRn drug fails in a pair of Phase 3 trials in thyroid eye disease

Published

5 days ago

on

Immunovant’s batoclimab failed in two late-stage trials in thyroid eye disease (TED). It already said it probably wasn’t going to advance the drug further in a similar condition called Graves’ disease.

The …

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version